Current reports
8-K
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
13 May 24
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
5 Mar 24
8-K
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
28 Aug 23
8-K
Departure of Directors or Certain Officers
21 Aug 23
8-K
Regulation FD Disclosure
7 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
13 May 24
424B4
Prospectus supplement with pricing info
11 Mar 24
S-1MEF
Registration of additional securities for an S-1
7 Mar 24
S-1
IPO registration
5 Mar 24
DRS
Draft registration statement
9 Feb 24
S-8
Registration of securities for employees
28 Aug 23
424B4
Prospectus supplement with pricing info
17 Jul 23
S-1MEF
Registration of additional securities for an S-1
13 Jul 23
8-A12B
Registration of securities on exchange
10 Jul 23
S-1/A
IPO registration (amended)
10 Jul 23
Other
EFFECT
Notice of effectiveness
8 Mar 24
SEC STAFF
SEC staff action: Order
25 Jul 23
EFFECT
Notice of effectiveness
14 Jul 23
CERT
Certification of approval for exchange listing
12 Jul 23
CORRESP
Correspondence with SEC
11 Jul 23
CORRESP
Correspondence with SEC
11 Jul 23
CORRESP
Correspondence with SEC
10 Jul 23
UPLOAD
Letter from SEC
30 Jun 23
CORRESP
Correspondence with SEC
22 Jun 23
UPLOAD
Letter from SEC
16 Jun 23
Ownership
4
Peter Evan Harwin
1 Apr 24
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Peter Evan Harwin
31 Jan 24
SC 13D/A
Fairmount Funds Management LLC
31 Jan 24
4
Carl Dambkowski
20 Dec 23
4
Jane Henderson
20 Dec 23
4
MICHAEL THOMAS HENDERSON
20 Dec 23